

20 July 2023

## Non-small cell lung cancer treatment

**In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments:**

**Atezolizumab:** See table below

**Durvalumab:** See table below

**Nivolumab:** See table below

**Pembrolizumab:** See table below

**Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only:** See table below

**Radiotherapy only:** 161

**Chemotherapy + radiotherapy:** 9

	Count of Local Patient Identifier
Atez/Bev/Carbo/Pac (NSCLC)	<5
Carboplatin & Vinorelbine XRT (NSCLC)	5
Cisplatin & Vinorelbine (NSCLC)	10
Cisplatin & Vinorelbine XRT (NSCLC)	<5
Durvalumab (NSCLC)	<5
Durvalumab 1500mg 4 weekly (NSCLC)	5
Gemcitabine & Carboplatin (NSCLC)	<5
Osimertinib (NSCLC)	<5
Osimertinib 84 day (NSCLC)	<5
Pembrolizumab 200mg 3 weekly (NSCLC)	7
Pembrolizumab 400mg 6 weekly (NSCLC)	10
Pembrolizumab/Pemetrexed/Carbo (NSCLC)	<5
Pemetrexed & Carboplatin (NSCLC)	<5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.